NuPathe Wins U.S. FDA Approval for First Migraine Skin Patch
This article is for subscribers only.
NuPathe Inc., a maker of neurological and psychiatric medicines, won U.S. approval to sell the first skin patch to treat migraines.
The Food and Drug Administration cleared the treatment, called Zecuity, which delivers sumatriptan, the most-prescribed migraine headache medication, through a mild electrical current, Conshohocken, Pennsylvania-based NuPathe said yesterday in a statement.